Published in Circ Res on February 18, 2010
Gap junctions. Compr Physiol (2012) 1.59
A novel desmocollin-2 mutation reveals insights into the molecular link between desmosomes and gap junctions. Heart Rhythm (2011) 1.54
Cardiomyocyte protein trafficking: Relevance to heart disease and opportunities for therapeutic intervention. Trends Cardiovasc Med (2014) 1.46
A peptide mimetic of the connexin43 carboxyl terminus reduces gap junction remodeling and induced arrhythmia following ventricular injury. Circ Res (2011) 1.29
Autophagy: a pathway that contributes to connexin degradation. J Cell Sci (2011) 1.17
Autophagy modulates dynamics of connexins at the plasma membrane in a ubiquitin-dependent manner. Mol Biol Cell (2012) 1.15
Connexins modulate autophagosome biogenesis. Nat Cell Biol (2014) 1.13
The connexin43 carboxyl terminus and cardiac gap junction organization. Biochim Biophys Acta (2011) 1.05
Internalized gap junctions are degraded by autophagy. Autophagy (2012) 1.04
Proteins and mechanisms regulating gap-junction assembly, internalization, and degradation. Physiology (Bethesda) (2013) 1.03
Systemic maternal inflammation and neonatal hyperoxia induces remodeling and left ventricular dysfunction in mice. PLoS One (2011) 1.02
Ultrastructural changes in cardiac myocytes from Boxer dogs with arrhythmogenic right ventricular cardiomyopathy. J Vet Cardiol (2011) 0.99
Connexin 43 is an emerging therapeutic target in ischemia/reperfusion injury, cardioprotection and neuroprotection. Pharmacol Ther (2015) 0.97
Phosphorylation on Ser-279 and Ser-282 of connexin43 regulates endocytosis and gap junction assembly in pancreatic cancer cells. Mol Biol Cell (2013) 0.95
Enhanced activation of p21-activated kinase 1 in heart failure contributes to dephosphorylation of connexin 43. Cardiovasc Res (2011) 0.94
Mammalian enabled (Mena) is a critical regulator of cardiac function. Am J Physiol Heart Circ Physiol (2011) 0.94
Pressure-overload-induced subcellular relocalization/oxidation of soluble guanylyl cyclase in the heart modulates enzyme stimulation. Circ Res (2011) 0.94
Connexins: mechanisms regulating protein levels and intercellular communication. FEBS Lett (2014) 0.93
Degradation of connexins and gap junctions. FEBS Lett (2014) 0.88
Novel mechanisms for caspase inhibition protecting cardiac function with chronic pressure overload. Basic Res Cardiol (2013) 0.87
Two tyrosine-based sorting signals in the Cx43 C-terminus cooperate to mediate gap junction endocytosis. Mol Biol Cell (2013) 0.87
Ubiquitination, intracellular trafficking, and degradation of connexins. Arch Biochem Biophys (2012) 0.86
Degradation of endocytosed gap junctions by autophagosomal and endo-/lysosomal pathways: a perspective. J Membr Biol (2012) 0.85
How to take autophagy and endocytosis up a notch. Biomed Res Int (2014) 0.85
The gap junction life cycle. Heart Rhythm (2011) 0.85
The molecular mechanisms of gap junction remodeling. Heart Rhythm (2011) 0.85
EGF induces efficient Cx43 gap junction endocytosis in mouse embryonic stem cell colonies via phosphorylation of Ser262, Ser279/282, and Ser368. FEBS Lett (2014) 0.83
Trafficking highways to the intercalated disc: new insights unlocking the specificity of connexin 43 localization. Cell Commun Adhes (2014) 0.80
Cerulein hyperstimulation decreases AMP-activated protein kinase levels at the site of maximal zymogen activation. Am J Physiol Gastrointest Liver Physiol (2012) 0.80
Improvement of cardiac function and reversal of gap junction remodeling by Neuregulin-1β in volume-overloaded rats with heart failure. J Geriatr Cardiol (2012) 0.79
Connexin: a potential novel target for protecting the central nervous system? Neural Regen Res (2015) 0.78
Helicobacter pylori VacA induces apoptosis by accumulation of connexin 43 in autophagic vesicles via a Rac1/ERK-dependent pathway. Cell Death Discov (2015) 0.78
Connexins: substrates and regulators of autophagy. BMC Cell Biol (2016) 0.78
Spontaneous cardiac calcinosis in BALB/cByJ mice. Comp Med (2013) 0.77
Kinase programs spatiotemporally regulate gap junction assembly and disassembly: Effects on wound repair. Semin Cell Dev Biol (2015) 0.76
Molecular mechanisms regulating formation, trafficking and processing of annular gap junctions. BMC Cell Biol (2016) 0.76
Connexin 31.1 degradation requires the Clathrin-mediated autophagy in NSCLC cell H1299. J Cell Mol Med (2014) 0.76
mTOR Regulates Gap Junction Alpha-1 Protein Trafficking in Sertoli Cells and Is Required for the Maintenance of Spermatogenesis in Mice. Biol Reprod (2016) 0.76
New Cell Adhesion Molecules in Human Ischemic Cardiomyopathy. PCDHGA3 Implications in Decreased Stroke Volume and Ventricular Dysfunction. PLoS One (2016) 0.75
Localisation Microscopy of Breast Epithelial ErbB-2 Receptors and Gap Junctions: Trafficking after γ-Irradiation, Neuregulin-1β, and Trastuzumab Application. Int J Mol Sci (2017) 0.75
Connexin 43 and CaV1.2 Ion Channel Trafficking in Healthy and Diseased Myocardium. Circ Arrhythm Electrophysiol (2016) 0.75
Evaluation of Connexin 43 Redistribution and Endocytosis in Astrocytes Subjected to Ischemia/Reperfusion or Oxygen-Glucose Deprivation and Reoxygenation. Biomed Res Int (2017) 0.75
Direct Exposure to Ethanol Disrupts Junctional Cell-Cell Contact and Hippo-YAP Signaling in HL-1 Murine Atrial Cardiomyocytes. PLoS One (2015) 0.75
Role of autophagy in the regulation of epithelial cell junctions. Tissue Barriers (2016) 0.75
The "tail" of Connexin43: An unexpected journey from alternative translation to trafficking. Biochim Biophys Acta (2015) 0.75
Connexins in Cardiovascular and Neurovascular Health and Disease: Pharmacological Implications. Pharmacol Rev (2017) 0.75
Nutrient Starvation Decreases Cx43 Levels and Limits Intercellular Communication in Primary Bovine Corneal Endothelial Cells. J Membr Biol (2016) 0.75
Intercalated disc in failing hearts from patients with dilated cardiomyopathy: Its role in the depressed left ventricular function. PLoS One (2017) 0.75
Autophagy in the pathogenesis of disease. Cell (2008) 34.68
Autophagy: from phenomenology to molecular understanding in less than a decade. Nat Rev Mol Cell Biol (2007) 10.79
The role of autophagy in cardiomyocytes in the basal state and in response to hemodynamic stress. Nat Med (2007) 8.82
Cardiac malformation in neonatal mice lacking connexin43. Science (1995) 5.51
Cardiac autophagy is a maladaptive response to hemodynamic stress. J Clin Invest (2007) 5.17
Conduction slowing and sudden arrhythmic death in mice with cardiac-restricted inactivation of connexin43. Circ Res (2001) 4.38
Biochemical analysis of connexin43 intracellular transport, phosphorylation, and assembly into gap junctional plaques. J Cell Biol (1991) 3.76
Microtubule plus-end-tracking proteins target gap junctions directly from the cell interior to adherens junctions. Cell (2007) 3.52
The gap junction protein connexin43 interacts with the second PDZ domain of the zona occludens-1 protein. Curr Biol (1998) 2.80
Rapid turnover of connexin43 in the adult rat heart. Circ Res (1998) 2.75
Five-hour half-life of mouse liver gap-junction protein. J Cell Biol (1981) 2.65
Zonula occludens-1 alters connexin43 gap junction size and organization by influencing channel accretion. Mol Biol Cell (2005) 2.62
Remodelling of gap junctions and connexin expression in diseased myocardium. Cardiovasc Res (2008) 2.43
Turnover and phosphorylation dynamics of connexin43 gap junction protein in cultured cardiac myocytes. Biochem J (1991) 2.33
Mechanisms underlying conduction slowing and arrhythmogenesis in nonischemic dilated cardiomyopathy. Circ Res (2004) 2.19
Connexin phosphorylation as a regulatory event linked to gap junction channel assembly. Biochim Biophys Acta (2004) 2.11
Dynamic changes in conduction velocity and gap junction properties during development of pacing-induced heart failure. Am J Physiol Heart Circ Physiol (2007) 1.94
Altered patterns of gap junction distribution in ischemic heart disease. An immunohistochemical study of human myocardium using laser scanning confocal microscopy. Am J Pathol (1991) 1.93
Slow ventricular conduction in mice heterozygous for a connexin43 null mutation. J Clin Invest (1997) 1.83
Connexin 43 downregulation and dephosphorylation in nonischemic heart failure is associated with enhanced colocalized protein phosphatase type 2A. Circ Res (2004) 1.75
Connexin phosphorylation as a regulatory event linked to gap junction internalization and degradation. Biochim Biophys Acta (2005) 1.70
Connexin family members target to lipid raft domains and interact with caveolin-1. Biochemistry (2002) 1.66
The gap junction protein connexin43 is degraded via the ubiquitin proteasome pathway. J Biol Chem (1995) 1.64
Internalization of large double-membrane intercellular vesicles by a clathrin-dependent endocytic process. Mol Biol Cell (2006) 1.46
Gap junction remodelling in human heart failure is associated with increased interaction of connexin43 with ZO-1. Cardiovasc Res (2007) 1.46
Altered patterns of cardiac intercellular junction distribution in hypertrophic cardiomyopathy. Heart (1996) 1.41
The origin of annular junctions: a mechanism of gap junction internalization. J Cell Sci (2001) 1.38
Ubiquitination and down-regulation of gap junction protein connexin-43 in response to 12-O-tetradecanoylphorbol 13-acetate treatment. J Biol Chem (2004) 1.34
Caveolin-1 and -2 interact with connexin43 and regulate gap junctional intercellular communication in keratinocytes. Mol Biol Cell (2007) 1.23
Functional reentry in cultured monolayers of neonatal rat cardiac cells. Am J Physiol Heart Circ Physiol (2003) 1.22
Evidence for the participation of actin microfilaments and bristle coats in the internalization of gap junction membrane. J Cell Biol (1979) 1.22
Fate of gap junctions in isolated adult mammalian cardiomyocytes. Circ Res (1989) 1.21
Gap junction remodeling in hypertrophied left ventricles of aortic-banded rats: prevention by angiotensin II type 1 receptor blockade. J Mol Cell Cardiol (2001) 1.19
Remodeling of gap junctional coupling in hypertrophied right ventricles of rats with monocrotaline-induced pulmonary hypertension. Circ Res (2000) 1.18
Modulation of cell junctions during differentiation of the chicken otocyst sensory epithelium. Dev Biol (1979) 1.14
Effects of angiotensin II on expression of the gap junction channel protein connexin43 in neonatal rat ventricular myocytes. J Am Coll Cardiol (1998) 1.07
Lipid rafts prepared by different methods contain different connexin channels, but gap junctions are not lipid rafts. Biochemistry (2005) 1.06
Fate of intercellular junctions in isolated adult rat cardiac cells. Circ Res (1985) 1.05
Endothelin-1 decreases gap junctional intercellular communication by inducing phosphorylation of connexin 43 in human ovarian carcinoma cells. J Biol Chem (2003) 1.05
Endocytic processing of connexin43 gap junctions: a morphological study. Biochem J (2006) 1.03
Origin and fate of cytoplasmic gap junctional vesicles in rabbit granulosa cells. Tissue Cell (1978) 0.99
Gap junction endocytosis and lysosomal degradation of connexin43-P2 in WB-F344 rat liver epithelial cells treated with DDT and lindane. Carcinogenesis (1996) 0.96
Zonula occludens-1 and connexin 43 expression in the failing human heart. J Cell Mol Med (2007) 0.94
Aberrant Connexin 43 endocytosis by the carcinogen lindane involves activation of the ERK/mitogen-activated protein kinase pathway. Carcinogenesis (2003) 0.93
Internalization and dephosphorylation of connexin43 in hypertrophied right ventricles of rats with pulmonary hypertension. Circ J (2007) 0.92
Autophagic sequestration of internalized gap junctions in rat liver. Eur J Cell Biol (1980) 0.91
Remodeling of gap junctions and slow conduction in a mouse model of desmin-related cardiomyopathy. Cardiovasc Res (2005) 0.90
Subchronic alpha- and beta-adrenergic regulation of cardiac gap junction protein expression. FASEB J (2005) 0.89
Inhibition of gap junctional intercellular communication by tumor promoters in connexin43 and connexin32-expressing liver cells: cell specificity and role of protein kinase C. Carcinogenesis (1998) 0.88
Signal transduction and transcriptional control of cardiac connexin43 up-regulation after alpha 1-adrenoceptor stimulation. J Pharmacol Exp Ther (2008) 0.88
Gap junction assembly and endocytosis correlated with patterns of growth in a cultured adrenocortical tumor cell (SW-13). Cancer Res (1981) 0.87
So-called annular gap junctions in bone cells of normal mice. Experientia (1977) 0.84
Acid phosphatase localization in endocytosed horizontal cell gap junctions. Vis Neurosci (1992) 0.78
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med (2004) 18.38
c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature (2009) 13.28
Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association's strategic Impact Goal through 2020 and beyond. Circulation (2010) 13.28
2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation (2013) 10.24
Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med (2005) 6.50
Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol (2005) 5.39
Infarct tissue heterogeneity by magnetic resonance imaging identifies enhanced cardiac arrhythmia susceptibility in patients with left ventricular dysfunction. Circulation (2007) 5.09
2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation (2013) 5.02
Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction: implications for systolic and diastolic reserve limitations. Circulation (2003) 4.51
Measurement of cardiac function using pressure-volume conductance catheter technique in mice and rats. Nat Protoc (2008) 4.50
Cardiac myosin activation: a potential therapeutic approach for systolic heart failure. Science (2011) 4.36
Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota. Circulation (2007) 3.78
2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation (2013) 3.63
Guidelines for the next 10 years of proteomics. Proteomics (2006) 3.61
Age- and gender-related ventricular-vascular stiffening: a community-based study. Circulation (2005) 3.34
Cardiac resynchronization and death from progressive heart failure: a meta-analysis of randomized controlled trials. JAMA (2003) 3.25
Oxidant stress from nitric oxide synthase-3 uncoupling stimulates cardiac pathologic remodeling from chronic pressure load. J Clin Invest (2005) 3.22
End-stage renal disease predicts complications in pacemaker and ICD implants. J Cardiovasc Electrophysiol (2011) 3.21
The mitochondrial origin of postischemic arrhythmias. J Clin Invest (2005) 3.08
Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction. Circulation (2006) 3.01
Late gadolinium enhancement by cardiovascular magnetic resonance heralds an adverse prognosis in nonischemic cardiomyopathy. J Am Coll Cardiol (2008) 2.99
Tackling heart failure in the twenty-first century. Nature (2008) 2.93
Systolic improvement and mechanical resynchronization does not require electrical synchrony in the dilated failing heart with left bundle-branch block. Circulation (2002) 2.88
Clinical proteomics: A need to define the field and to begin to set adequate standards. Proteomics Clin Appl (2007) 2.84
Magnetic resonance assessment of the substrate for inducible ventricular tachycardia in nonischemic cardiomyopathy. Circulation (2005) 2.80
Circulating transforming growth factor-beta in Marfan syndrome. Circulation (2009) 2.69
Optimal left ventricular endocardial pacing sites for cardiac resynchronization therapy in patients with ischemic cardiomyopathy. J Am Coll Cardiol (2010) 2.66
Cardiac magnetic resonance assessment of dyssynchrony and myocardial scar predicts function class improvement following cardiac resynchronization therapy. JACC Cardiovasc Imaging (2008) 2.64
Combined cardiac magnetic resonance imaging and C-reactive protein levels identify a cohort at low risk for defibrillator firings and death. Circ Cardiovasc Imaging (2012) 2.62
Cardiovascular features of heart failure with preserved ejection fraction versus nonfailing hypertensive left ventricular hypertrophy in the urban Baltimore community: the role of atrial remodeling/dysfunction. J Am Coll Cardiol (2006) 2.61
Role of oxidative stress in cardiac hypertrophy and remodeling. Hypertension (2006) 2.59
Genetic variations in nitric oxide synthase 1 adaptor protein are associated with sudden cardiac death in US white community-based populations. Circulation (2009) 2.55
Cost effectiveness of cardiac resynchronization therapy in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial. J Am Coll Cardiol (2005) 2.53
High-dose folic acid pretreatment blunts cardiac dysfunction during ischemia coupled to maintenance of high-energy phosphates and reduces postreperfusion injury. Circulation (2008) 2.47
Sex-steroid hormones and electrocardiographic QT-interval duration: findings from the third National Health and Nutrition Examination Survey and the Multi-Ethnic Study of Atherosclerosis. Am J Epidemiol (2011) 2.38
Sildenafil inhibits beta-adrenergic-stimulated cardiac contractility in humans. Circulation (2005) 2.38
PI3K rescues the detrimental effects of chronic Akt activation in the heart during ischemia/reperfusion injury. J Clin Invest (2005) 2.36
Animal models of heart failure: a scientific statement from the American Heart Association. Circ Res (2012) 2.31
The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model. J Clin Invest (2002) 2.26
Phosphodiesterase-5A dysregulation in penile erectile tissue is a mechanism of priapism. Proc Natl Acad Sci U S A (2005) 2.25
L-arginine therapy in acute myocardial infarction: the Vascular Interaction With Age in Myocardial Infarction (VINTAGE MI) randomized clinical trial. JAMA (2006) 2.24
Cytoprotective role of Ca2+- activated K+ channels in the cardiac inner mitochondrial membrane. Science (2002) 2.23
Retiming the failing heart: principles and current clinical status of cardiac resynchronization. J Am Coll Cardiol (2002) 2.22
The future of fellowship training in clinical cardiac electrophysiology: Program directors' perspective 2008. Heart Rhythm (2009) 2.22
Proteomic analysis of pharmacological preconditioning: novel protein targets converge to mitochondrial metabolism pathways. Circ Res (2006) 2.20
Mechanisms underlying conduction slowing and arrhythmogenesis in nonischemic dilated cardiomyopathy. Circ Res (2004) 2.19
Identification and characterization of a functional mitochondrial angiotensin system. Proc Natl Acad Sci U S A (2011) 2.16
Avoidance of transient cardiomyopathy in cardiomyocyte-targeted tamoxifen-induced MerCreMer gene deletion models. Circ Res (2009) 2.11
Uromodulin levels associate with a common UMOD variant and risk for incident CKD. J Am Soc Nephrol (2009) 2.10
Cardiac dyssynchrony analysis using circumferential versus longitudinal strain: implications for assessing cardiac resynchronization. Circulation (2005) 2.09
Post-transcriptional gene silencing of KChIP2 and Navbeta1 in neonatal rat cardiac myocytes reveals a functional association between Na and Ito currents. J Mol Cell Cardiol (2008) 2.09
Electrophysiological consequences of dyssynchronous heart failure and its restoration by resynchronization therapy. Circulation (2009) 2.09
Acute phosphodiesterase 5 inhibition mimics hemodynamic effects of B-type natriuretic peptide and potentiates B-type natriuretic peptide effects in failing but not normal canine heart. J Am Coll Cardiol (2007) 2.07
Cardiac resynchronization therapy: Part 1--issues before device implantation. J Am Coll Cardiol (2005) 2.06
Impact of arterial load and loading sequence on left ventricular tissue velocities in humans. J Am Coll Cardiol (2007) 2.05
Multiple reaction monitoring to identify site-specific troponin I phosphorylated residues in the failing human heart. Circulation (2012) 2.05
Referral, enrollment, and delivery of cardiac rehabilitation/secondary prevention programs at clinical centers and beyond: a presidential advisory from the American Heart Association. Circulation (2011) 2.05
Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension. J Hypertens (2007) 2.01
Cardiac resynchronization therapy: Part 2--issues during and after device implantation and unresolved questions. J Am Coll Cardiol (2005) 1.98
Dual antiplatelet therapy and heparin "bridging" significantly increase the risk of bleeding complications after pacemaker or implantable cardioverter-defibrillator device implantation. J Am Coll Cardiol (2010) 1.97
Gaps in the ablation line as a potential cause of recovery from electrical isolation and their visualization using MRI. Circ Arrhythm Electrophysiol (2011) 1.95
Functional impact of rate irregularity in patients with heart failure and atrial fibrillation receiving cardiac resynchronization therapy. Eur Heart J (2004) 1.95
Dynamic changes in conduction velocity and gap junction properties during development of pacing-induced heart failure. Am J Physiol Heart Circ Physiol (2007) 1.94
Mitotic chromosomes are compacted laterally by KIF4 and condensin and axially by topoisomerase IIα. J Cell Biol (2012) 1.94
Pivotal role of cardiomyocyte TGF-β signaling in the murine pathological response to sustained pressure overload. J Clin Invest (2011) 1.94
Pulmonary capillary wedge pressure augments right ventricular pulsatile loading. Circulation (2011) 1.92
Compartmentalized phosphodiesterase-2 activity blunts beta-adrenergic cardiac inotropy via an NO/cGMP-dependent pathway. Circ Res (2005) 1.91
Na+ channel regulation by Ca2+/calmodulin and Ca2+/calmodulin-dependent protein kinase II in guinea-pig ventricular myocytes. Cardiovasc Res (2009) 1.88
Ventricular-arterial coupling, remodeling, and prognosis in chronic heart failure. J Am Coll Cardiol (2013) 1.86
Beat-to-beat three-dimensional ECG variability predicts ventricular arrhythmia in ICD recipients. Heart Rhythm (2010) 1.85
Small-molecule therapies for cardiac hypertrophy: moving beneath the cell surface. Nat Rev Drug Discov (2007) 1.83
Reversal of cardiac hypertrophy and fibrosis from pressure overload by tetrahydrobiopterin: efficacy of recoupling nitric oxide synthase as a therapeutic strategy. Circulation (2008) 1.82
Regulator of G protein signaling 2 mediates cardiac compensation to pressure overload and antihypertrophic effects of PDE5 inhibition in mice. J Clin Invest (2009) 1.79
Tyrosine 23 phosphorylation-dependent cell-surface localization of annexin A2 is required for invasion and metastases of pancreatic cancer. PLoS One (2011) 1.79
A biochemical rationale for the discrete behavior of nitroxyl and nitric oxide in the cardiovascular system. Proc Natl Acad Sci U S A (2003) 1.78
Sildenafil stops progressive chamber, cellular, and molecular remodeling and improves calcium handling and function in hearts with pre-existing advanced hypertrophy caused by pressure overload. J Am Coll Cardiol (2009) 1.77
Positive inotropic and lusitropic effects of HNO/NO- in failing hearts: independence from beta-adrenergic signaling. Proc Natl Acad Sci U S A (2003) 1.76
Characterization of the cardiac myosin binding protein-C phosphoproteome in healthy and failing human hearts. J Mol Cell Cardiol (2013) 1.75
QT-interval duration and mortality rate: results from the Third National Health and Nutrition Examination Survey. Arch Intern Med (2011) 1.73
cGMP catabolism by phosphodiesterase 5A regulates cardiac adrenergic stimulation by NOS3-dependent mechanism. Circ Res (2004) 1.73
Modulation of Kv4.3 current by accessory subunits. FEBS Lett (2002) 1.72
Cardioprotective effect of beta-3 adrenergic receptor agonism: role of neuronal nitric oxide synthase. J Am Coll Cardiol (2012) 1.72
Hyperactive adverse mechanical stress responses in dystrophic heart are coupled to transient receptor potential canonical 6 and blocked by cGMP-protein kinase G modulation. Circ Res (2014) 1.70
Imbalance between xanthine oxidase and nitric oxide synthase signaling pathways underlies mechanoenergetic uncoupling in the failing heart. Circ Res (2002) 1.70
Bioartificial sinus node constructed via in vivo gene transfer of an engineered pacemaker HCN Channel reduces the dependence on electronic pacemaker in a sick-sinus syndrome model. Circulation (2006) 1.70
Investigation of an albumin-enriched fraction of human serum and its albuminome. Proteomics Clin Appl (2007) 1.68